Engineered Effector Cells for ADCC and ADCP Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for determining antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) suffer from limitations such as variability in effector cells, restricted dynamic range, poor sensitivity, and imprecision, making it difficult to accurately quantify the effectiveness of monoclonal antibodies.
Innovation Solution
Engineered cells over-expressing co-stimulatory molecules like CD80, CD86, and CD137, combined with recombinant effector and target cells, enhance the dynamic range and sensitivity of ADCC and ADCP assays by interacting with Fc receptors, thereby improving the quantification of antibody activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endogenous effector cells are harvested from human subjects, then the assay can be performed with natural cells, but there is great variability in the cells being used and substantial variation from donor to donor
Solution Approach 1:
The patent uses recombinant effector cell lines that replicate the function of natural NK cells but with consistent, engineered properties. These cell lines express FcγRIIIa (CD16) at controlled levels and can be produced in unlimited quantities with identical characteristics, eliminating donor variability while maintaining biological relevance.
Solution Approach 2:
The patent modifies key parameters of effector cells by engineering cell lines with specific FcγRIIIa expression levels and characteristics. By controlling cell surface receptor expression and cell line genetics, the patent standardizes effector cell properties across experiments while preserving their immune-mediated cytotoxicity function.
2Measurement precision
If classic chromium-loaded target cells are used, then cell killing can be determined by chromium release, but the assays are long and protracted and often have to be incubated overnight
Solution Approach 1:
The patent replaces the mechanical chromium release measurement system with a biochemical reporter gene system. Effector cells express luciferase under the control of an NFAT-responsive promoter, converting the mechanical measurement of cell lysis into a biochemical luminescence signal that can be detected rapidly and quantified with high precision.
Solution Approach 2:
The patent introduces an intermediary signaling pathway using NFAT transcription factor and luciferase reporter gene. This intermediary system translates the biological event of FcγRIIIa-mediated cytotoxicity into a measurable luminescence signal, enabling rapid detection without requiring overnight incubation or chromium release measurements.
3Measurement precision
If the dynamic range is restricted in current assays, then the assay is simpler to perform, but the sensitivity is poor and detection of small differences between antibody variants is difficult
Solution Approach 1:
The patent optimizes multiple parameters simultaneously: FcγRIIIa expression level on effector cells, NFAT promoter responsiveness, and luciferase reporter sensitivity. By tuning these parameters, the patent expands the dynamic range to cover 3-4 log units while maintaining simplicity of execution, enabling detection of subtle differences between antibody variants.
Solution Approach 2:
The patent creates a composite assay system combining recombinant effector cells with engineered FcγRIIIa expression, NFAT-responsive promoter elements, and luciferase reporter genes. This composite system integrates multiple functional components that work together to provide enhanced sensitivity and dynamic range while maintaining operational simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in a significantly improved EC50 and Lower Limit of Quantification (LLOQ), increasing sensitivity and dynamic range by at least 10-fold compared to existing techniques, allowing for more precise detection of antibody effectiveness.
Implementation Method 1
the Fc receptor moiety of an effector cell will bind to the Fc portion of the monoclonal antibody and thereby effect killing of the target cell by the effector cell
Implementation Method 2
activation of the firefly luciferase (FL) reporter gene and the emission of light that can be quantified in a luminometer
Implementation Method 3
recombinant effector and target cells, enhance the dynamic range and sensitivity of ADCC and ADCP assays by interacting with Fc receptors
Data Source
AI summary
The present invention relates novel cells and their use in methods for determining the antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP) in a sample.